Publicaciones en colaboración con investigadores/as de Pierre and Marie Curie University (11)

2019

  1. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

    Nature Communications, Vol. 10, Núm. 1

2016

  1. Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma

    Cancer Investigation, Vol. 34, Núm. 1, pp. 39-44

2015

  1. VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab

    Journal of Neuro-Oncology, Vol. 121, Núm. 3, pp. 499-504

  2. Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types

    Journal of the National Cancer Institute, Vol. 107, Núm. 12

2014

  1. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma

    Cancer, Vol. 120, Núm. 24, pp. 3972-3980

  2. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33

    Human Molecular Genetics, Vol. 23, Núm. 24, pp. 6616-6633

  3. Management of elderly patients with gliomas

    Oncologist, Vol. 19, Núm. 12, pp. 1258-1267

2012

  1. Detection of IDH1 mutation in the plasma of patients with glioma

    Neurology, Vol. 79, Núm. 16, pp. 1693-1698

  2. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: Comparative analysis of the Macdonald, RECIST, RANO, and RECIST F criteria

    Neuro-Oncology, Vol. 14, Núm. 5, pp. 667-673

  3. Sporadic CNS hemangioblastomatosis, response to sunitinib and secondary polycythemia

    Journal of Neuro-Oncology

2011

  1. Erratum to: Sporadic CNS hemangioblastomatosis, response to sunitinib and secondary polycythemia (Journal of Neuro-Oncology DOI: 10.1007/s11060-011-0752- 9)

    Journal of Neuro-Oncology